Loading…
Manufactures active pharmaceutical ingredients (APIs) and offers contract development/manufacturing services to global pharma companies.
Manufactures active pharmaceutical ingredients (APIs) and offers contract development/manufacturing services to global pharma companies.
Sells generic active ingredients (the part of a medicine that works) in volume to generic drugmakers, where customers qualify the plant and product before ordering, and does custom synthesis under contract for innovator companies at higher value. The founding family leads the company.
In one line: A mid-sized Indian API/CDMO player.
Moat: narrow (regulatory licence, process know-how). US FDA/EU-approved API plants and chemistry expertise support long-term supply contracts.
Headquarters: Hyderabad, India · Founded: 1984 · Employees: 3,881
Size Neuland Laboratories (NEULANDLAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $2.68B, the 312th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹19,700 on 6 Nov 2026.
Performance Over six months the shares gained 14.0%, against -4.7% for the median peer and 0.0% for the India market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 50.5% over the last twelve months (peer median +4.2%); the operating margin is 26.0% (peer median 9.1%).
Valuation It trades at 54.3× forward earnings against a peer median of 42.5× (5th most expensive of 15).
Capital Return on invested capital runs 7.0 points above its cost of capital (16.3% WACC).
Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹23.1B | ₹20.0B | ₹14.5B | ₹15.3B | ₹11.8B |
| Revenue growth | — | +37% | -5% | +31% | — |
| Gross profit | ₹7.65B | ₹6.33B | ₹3.82B | ₹4.99B | ₹3.07B |
| EBITDA | ₹7.05B | ₹5.61B | ₹3.12B | ₹4.46B | ₹2.69B |
| Net income | ₹4.53B | ₹3.64B | ₹2.60B | ₹3.00B | ₹1.64B |
| Free cash flow | n/a | -₹589M | ₹1.13B | ₹1.12B | ₹1.60B |
| Capital expenditure | n/a | ₹3.97B | ₹2.06B | ₹1.44B | ₹661M |
| Total debt | ₹3.42B | ₹3.01B | ₹1.57B | ₹954M | ₹1.28B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Neuland Laboratories NEULANDLAB.NS | $2.68B | +14% | +50% | 26% | 54.3× | n/a |
| Divi's Laboratories DIVISLAB.NS | $29.0B | +54% | +16% | 31% | 82.0× | 50.9% |
| Laurus Labs LAURUSLABS.NS | $13.3B | +94% | +23% | 24% | 77.0× | 50.9% |
| Piramal Pharma PPLPHARMA.NS | $3.37B | +30% | +9% | 3% | 159.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NEULANDLAB.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.0% | -0.2% | 7th lowest of 21 |
| 6-month return | +14.0% | -4.7% | 5th highest of 21 |
| Distance from 52-week high | -18.7% | -25.2% | 8th highest of 21 |
| Revenue growth (TTM) | +50.5% | +4.2% | 4th highest of 20 |
| Operating margin | 26.0% | 9.1% | 3rd highest of 19 |
| Forward P/E | 54.3× | 42.5× | 5th most expensive of 15 |
| ROIC minus cost of capital | +7.0 pp | -1.3 pp | 3rd highest of 16 |
| EV / EBITDA | 35.8× | n/a | — |
| Net debt / EBITDA | -0.1× | -1.7× | 2nd most indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Neuland Laboratories NEULANDLAB.NS | India | $2.68B | +14% | +50% | 26% | 54.3× | n/a | n/a |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.70B | -20% | -14% | 16% | 26.3× | 4.6% | +4.8% |
| Acrobiosystems 301080.SZ | China | $2.72B | +95% | +29% | 17% | 64.9× | 45.0% | +27.7% |
| Almirall ALM.MC | Spain | $2.74B | -2% | +24% | 8% | 30.6× | 7.3% | +6.5% |
| Regencell Bioscience RGC | United States | $2.61B | -82% | n/a | n/a | n/a | n/a | n/a |
| Kangmei Pharmaceutical 600518.SS | China | $2.77B | -22% | -6% | -7% | n/a | n/a | n/a |
| BioArctic BIOA-B.ST | Sweden | $2.78B | -3% | -46% | 22% | 53.4× | 25.7% | +100.1% |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.58B | +9% | -9% | -6% | 40.8× | 49.9% | +19.3% |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.80B | -43% | +153% | -7% | 100.0× | 42.1% | +22.9% |
| Vericel VCEL | United States | $2.80B | +63% | +23% | 6% | 76.2× | 50.7% | +17.3% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.86B | -4% | -12% | 18% | 15.6× | -13.1% | +2.4% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.48B | -6% | 0% | -73% | 18.6× | n/a | n/a |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.91B | -59% | +21% | 7% | n/a | n/a | n/a |
| Betta Pharmaceuticals 300558.SZ | China | $3.01B | -9% | +16% | 11% | 44.2× | 25.2% | +14.0% |
| IDEAYA Biosciences IDYA | United States | $3.02B | +10% | -83% | -1,267% | n/a | n/a | n/a |
| Hybio Pharmaceutical 300199.SZ | China | $3.08B | +16% | +70% | 31% | 51.4× | 40.1% | +6.1% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.32B | +18% | -7% | 15% | 17.0× | -9.1% | -1.5% |
| InnoCare Pharma 688428.SS | China | $2.31B | -2% | +135% | 35% | 94.3× | -8.8% | +344.2% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.31B | -7% | +4% | 10% | n/a | -2.2% | -5.8% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.29B | -14% | +18% | n/a | 26.2× | 1.6% | +0.3% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.26B | -35% | 0% | -47% | n/a | n/a | n/a |